Jan J Melenhorst
Overview
Explore the profile of Jan J Melenhorst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
6915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gofshteyn J, Shaw P, Teachey D, Grupp S, Maude S, Banwell B, et al.
Ann Neurol
. 2018 Sep;
84(4):537-546.
PMID: 30178481
Objective: To characterize the incidence and clinical characteristics of neurotoxicity in the month following CTL019 infusion in children and young adults, to define the relationship between neurotoxicity and cytokine release...
2.
Schuster S, Svoboda J, Chong E, Nasta S, Mato A, Anak O, et al.
N Engl J Med
. 2017 Dec;
377(26):2545-2554.
PMID: 29226764
Background: Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been...
3.
Obstfeld A, Frey N, Mansfield K, Lacey S, June C, Porter D, et al.
Blood
. 2017 Oct;
130(23):2569-2572.
PMID: 29074500
No abstract available.
4.
ORourke D, Nasrallah M, Desai A, Melenhorst J, Mansfield K, Morrissette J, et al.
Sci Transl Med
. 2017 Jul;
9(399).
PMID: 28724573
We conducted a first-in-human study of intravenous delivery of a single dose of autologous T cells redirected to the epidermal growth factor receptor variant III (EGFRvIII) mutation by a chimeric...
5.
Rubin C, Elenitsas R, Taylor L, Lacey S, Kulikovskaya I, Gupta M, et al.
J Am Acad Dermatol
. 2016 Oct;
75(5):1054-1057.
PMID: 27745631
No abstract available.
6.
Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J, et al.
J Clin Invest
. 2016 Aug;
126(10):3814-3826.
PMID: 27571406
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative...
7.
Bhoj V, Arhontoulis D, Wertheim G, Capobianchi J, Callahan C, Ellebrecht C, et al.
Blood
. 2016 May;
128(3):360-70.
PMID: 27166358
The mechanisms underlying the maintenance of long-lasting humoral immunity are not well understood. Studies in mice indicate that plasma cells (PCs) can survive up to a lifetime, even in the...
8.
Chen F, Teachey D, Pequignot E, Frey N, Porter D, Maude S, et al.
J Immunol Methods
. 2016 Apr;
434:1-8.
PMID: 27049586
T cells expressing a CD19-specific chimeric antigen receptor (CAR19) are demonstrating remarkable efficacy in hematologic malignancies. Treatment is often associated with life-threatening cytokine release syndrome (CRS) which can be effectively...
9.
Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G, et al.
Cancer Discov
. 2015 Oct;
5(12):1282-95.
PMID: 26516065
Unlabelled: The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor-armed T cells (CART-19), but relapses with epitope loss occur in 10%...
10.
Porter D, Hwang W, Frey N, Lacey S, Shaw P, Loren A, et al.
Sci Transl Med
. 2015 Sep;
7(303):303ra139.
PMID: 26333935
Patients with multiply relapsed or refractory chronic lymphocytic leukemia (CLL) have a poor prognosis. Chimeric antigen receptor (CAR)-modified T cells targeting CD19 have the potential to improve on the low...